{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:00:53Z","timestamp":1740146453331,"version":"3.37.3"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0212832","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T18:41:16Z","timestamp":1551379276000},"page":"e0212832","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-4799","authenticated-orcid":true,"given":"Nurul-Ain","family":"Mohd-Tahir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Chuen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"issue":"1","key":"ref1","first-page":"20","article-title":"Non-communicable diseases in the Asia-Pacific region: Prevalence, risk factors and community-based prevention","volume":"28","author":"W-Y Low","year":"2015","journal-title":"Int J Occup Med Environ Health"},{"key":"ref2","unstructured":"MOH. Annual Report 2011, Ministry of Health Malaysia. Putrajaya: Ministry of health Malaysia; 2011."},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.dsx.2012.03.001","article-title":"Prevalence of hypertension, control of blood pressure and treatment in hypertensive with type 2 diabetes in Hospital University Sains Malaysia","volume":"5","author":"SSI Abougalambou","year":"2011","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2369-15-15","article-title":"Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review","volume":"15","author":"Y Huang","year":"2014","journal-title":"BMC Nephrol"},{"issue":"4 suppl 2","key":"ref5","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1681\/ASN.2005121323","article-title":"Economic Evaluation of Angiotensin Receptor Blockers in Type 2 Diabetes, Hypertension, and Nephropathy","volume":"17","author":"M Ravera","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00019053-200624060-00001","article-title":"Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making","volume":"24","author":"C Boersma","year":"2006","journal-title":"PharmacoEconomics"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1524-4733.2007.00250.x","article-title":"An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy","volume":"11","author":"L Annemans","year":"2008","journal-title":"Value Health"},{"key":"ref8","unstructured":"Goh B, Ong L. Twenty second Report of the Malaysian Dialysis and Transplant 2014. Kuala Lumpur2015."},{"issue":"9200","key":"ref9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"EJ Lewis","year":"2001","journal-title":"The New England journal of medicine"},{"issue":"20","key":"ref11","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"EJ Lewis","year":"1993","journal-title":"The New England journal of medicine"},{"issue":"9638","key":"ref12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"JF Mann","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.jhh.1001729","article-title":"An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting","volume":"18","author":"AJ Palmer","year":"2004","journal-title":"J Hum Hypertens"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/S0149-2918(03)80208-4","article-title":"The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy","volume":"25","author":"RA Rodby","year":"2003","journal-title":"Clin Ther"},{"issue":"4","key":"ref15","first-page":"CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","author":"GF Strippoli","year":"2006","journal-title":"The Cochrane database of systematic reviews"},{"key":"ref16","first-page":"f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"HY Wu","year":"2013","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget Impact Analysis\u2014Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"SD Sullivan","year":"2014","journal-title":"Value Health"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5694\/j.1326-5377.2010.tb03506.x","article-title":"Diabetic kidney disease: act now or pay later","volume":"192","author":"RC Atkins","year":"2010","journal-title":"Medical Journal of Australia"},{"key":"ref19","first-page":"2050312115596864","article-title":"Quality use of medicine in a developing economy: Measures to overcome challenges in the Malaysian healthcare system","volume":"3","author":"N-A Mohd-Tahir","year":"2015","journal-title":"SAGE Open Medicine"},{"key":"ref20","unstructured":"IPH. Institute of Public Health. National Health and Morbidity Survey 2015 (NHMS 2015). Vol. II: Non-Communicable Diseases, Risk Factors &amp; Other Health Problems. Kuala Lumpur: Ministry of Health; 2015."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1471-2458-7-234","article-title":"Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence","volume":"7","author":"CR Stevenson","year":"2007","journal-title":"BMC Public Health"},{"key":"ref22","unstructured":"PSD. Malaysian Statistics on Medicines 2009 &amp;2010. Kuala Lumpur, Malaysia: Pharmaceutical Services Division and Clinical Research Centre, Ministry of Health Malaysia; 2014."},{"key":"ref23","unstructured":"World Health Organization, Life tables for 194 countries. World mortality in 2015. [Internet]. 2015 [cited January 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/gho\/data\/view.main.60990?lang=en\" xlink:type=\"simple\">http:\/\/apps.who.int\/gho\/data\/view.main.60990?lang=en<\/ext-link>."},{"issue":"3","key":"ref24","first-page":"18","article-title":"Cost analysis of hypertension management in an urban primary medical centre Kuala Lumpur","volume":"14","author":"A Azimatun Noor","year":"2014","journal-title":"Malaysian Journal of Public Health Medicine"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1440-1797.2005.00360.x","article-title":"Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia","volume":"10","author":"LS Hooi","year":"2005","journal-title":"Nephrology (Carlton, Vic)"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.2337\/dc07-0150","article-title":"Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP)","volume":"30","author":"A Ramachandran","year":"2007","journal-title":"Diabetes Care"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1185\/030079908X261131","article-title":"An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies","volume":"24","author":"M Mohamed","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1524-4733.2008.00423.x","article-title":"Prescribing Trends and Drug Budget Impact of the ARBs in the UK","volume":"12","author":"BT Blak","year":"2009","journal-title":"Value in Health"},{"key":"ref29","unstructured":"MOH. Clinical Practice Guidelines for the Management of Type 2 Diabetes Mellitus. 5th ed. Kuala Lumpur: Joint Publication of the Ministry of Health Malaysia, Academy of Medicine Malaysia, Malaysian Endocrine &amp; Metabolic Society and Diabetes Malaysia; 2015."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0212832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:11:58Z","timestamp":1589001118000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0212832"}},"subtitle":[],"editor":[{"given":"Harald","family":"Mischak","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0212832","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,2,28]]}}}